InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2023-07-10 | Daniel Goldman(D-NY10) | house | Sale | $15,001 - $50,000 |
| 2023-03-31 | Daniel Goldman(D-NY10) | house | Sale | $15,001 - $50,000 |
| 2023-02-27 | Daniel Goldman(D-NY10) | house | Purchase | $15,001 - $50,000 |
| 2023-01-13 | Daniel Goldman(D-NY10) | house | Purchase | $1,001 - $15,000 |
| 2019-04-11 | Donna Shalala | house | Sale | $1,001 - $15,000 |
No financial data available for BAYRY.
Company may not file with SEC or CIK is unresolved.
Microsoft says it has over 20M paid Copilot users, and they really are using it
Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength
Regeneron shares slide despite Q1 beat
Regeneron drops despite Q1 beat, $3B share buyback program
Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian
New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing
Bayer Aktiengesellschaft (BAYRY) Shareholder/Analyst Call Transcript
HERVolution Therapeutics Appoints Dr. László B. Tankó to Scientific Advisory Board to Strengthen Cardiometabolic Clinical Development Strategy
Is It Too Late To Consider Bayer (XTRA:BAYN) After A 67.5% One-Year Surge?
Recursion Pharmaceuticals May Be Losing Ground To Its Peers